Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax-Reference-Cited by-同舟云学术

Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax

Published:2017-06-22 Issue:25 Volume:129 Page:3362-3370
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Anderson Mary Ann¹²³⁴,Tam Constantine³⁴⁵,Lew Thomas E.²,Juneja Surender¹⁴,Juneja Manu²,Westerman David⁴⁵,Wall Meaghan³⁶⁷,Lade Stephen⁴⁵,Gorelik Alexandra⁸,Huang David C. S.²³,Seymour John F.³⁴⁵,Roberts Andrew W.¹²³⁴^ORCID

Affiliation:

1. Department of Clinical Haematology and Bone Marrow Transplantation, The Royal Melbourne Hospital, Parkville, Australia;

2. Division of Cancer and Haematology, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia;

3. Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, Australia;

4. Victorian Comprehensive Cancer Centre, Parkville, Australia;

5. Peter MacCallum Cancer Centre, Parkville, Australia;

6. Victorian Cancer Cytogenetics Service, St Vincent’s Hospital, Fitzroy, Australia;

7. St Vincent’s Institute of Medical Research, Fitzroy, Australia; and

8. Melbourne Epicentre, The Royal Melbourne Hospital, Parkville, Australia

Abstract

Key Points Complex karyotype and fludarabine refractoriness are key risk factors for progression of CLL on venetoclax. Bruton tyrosine kinase inhibitors are active in patients with CLL after prior therapy with venetoclax.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/129/25/3362/1364094/blood763003.pdf

Reference24 articles.

1. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia;Roberts;N Engl J Med,2016

2. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study;Seymour;Lancet Oncol,2017

3. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome;Robertson;Leukemia,1996

4. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737;Del Gaizo Moore;J Clin Invest,2007

5. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets;Souers;Nat Med,2013

Cited by 146 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The molecular map of CLL and Richter's syndrome;Seminars in Hematology;2024-01

2. The New Face of Autophagy in Chronic Lymphocytic Leukemia;Cancers;2023-11-03

3. Richter transformation – retrospective treatment outcomes analysis in Polish Adult Leukemia Study Group;Leukemia & Lymphoma;2023-11-03

4. From genetics to therapy: Unraveling the complexities of Richter transformation in chronic lymphocytic leukemia;Cancer Treatment Reviews;2023-11

5. Prognostic Markers in the Era of Targeted Therapies;Acta Haematologica;2023-09-13